“Pharma bro” Martin Shkreli is also a deadbeat, according to court papers.

He owes nearly $1.7 million to financial services firm Marks Paneth, a Manhattan Supreme Court filing says.

The disgraced former pharmaceutical exec was sentenced to seven years in prison in 2017 for securities fraud and barred from the industry.

He gained infamy in 2015 when his Turing Pharmaceuticals acquired the rights to the life-saving cancer and AIDS drug Daraprim, and jacked the price from $13.50 per pill to $750.

“I owe Marks Paneth $1,695,063.00 in professional service fees for work performed on my behalf,” Shkreli, who was released from prison last year and now lives in Elmhurst, Queens, wrote in recently filed legal papers affirming the debt.

A lawyer for Marks Paneth did not respond to a message seeking comment and it’s unclear what work the company did for Shkreli.

Shkreli, who was banned from the pharmaceutical industry for life, also owed $1.6 million in taxes as of January.